SCHEMBL4789558

SCHEMBL4789558

CS(=O)(=O)Nc1cccc(C(=O)NCc2nc(-c3c[nH]c4ncccc34)cs2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 18/20 0.62
ROCK1 Q13464 17/20 0.62
CIT O14578 1/20 0.62
MAP3K7 O43318 1/20 0.62
JAK2 O60674 1/20 0.62
RPS6KA5 O75582 1/20 0.62
RPS6KA4 O75676 1/20 0.62
PRKCG P05129 1/20 0.62
PRKCB P05771 1/20 0.62
CCNA2 P20248 1/20 0.62
RPS6KB1 P23443 1/20 0.62
CDK2 P24941 1/20 0.62
MAPK1 P28482 1/20 0.62
FLT3 P36888 1/20 0.62
GSK3B P49841 1/20 0.62
IRAK1 P51617 1/20 0.62
RPS6KA3 P51812 1/20 0.62
JAK3 P52333 1/20 0.62
CDK5 Q00535 1/20 0.62
PRKCE Q02156 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4789114 0.84 ROCK1 (0.61) CYP3A4ROCK1CITJAK2RPS6KB1
SCHEMBL5114855 0.81 ROCK2 (0.52) CYP3A4ROCK1CITMAP3K7JAK2
SCHEMBL13887911 0.80 CYP3A4 (0.61) CYP3A4ROCK1CITMAP3K7JAK2
SCHEMBL4789848 0.78 ROCK1 (0.59) CYP3A4ROCK1CITMAP3K7JAK2
SCHEMBL4789857 0.77 PDPK1 (0.58) CYP3A4ROCK1CITMAP3K7JAK2
SCHEMBL13887721 0.77 ROCK1 (1.00) CYP3A4ROCK1CITMAP3K7JAK2
SCHEMBL13887890 0.76 CYP3A4 (0.70) CYP3A4ROCK1CITMAP3K7JAK2
SCHEMBL13888012 0.75 ROCK1 (0.71) CYP3A4ROCK1CITMAP3K7JAK2
SCHEMBL13888019 0.74 ROCK1 (0.70) CYP3A4ROCK1CITMAP3K7JAK2
SCHEMBL13306445 0.74 PDPK1 (0.53) CYP3A4ROCK1CITMAP3K7JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008011557-A2 HETEROARYL INHIBITORS OF RHO KINASE BORCHARDT ALLEN J (US) 2008-01-24 WO disclosed
WO-2008011557-A2 HETEROARYL INHIBITORS OF RHO KINASE BORCHARDT ALLEN J (US) 2008-01-24 WO disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 US disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 US disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE ROCK1, ROCK2, RHOA CYP3A4 4367/4885ROCK1 1/4885CIT 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.